Biotech's tax agenda

WASHINGTON - The Biotechnology Industry Organization wants a capital gains incentive as well as a second-tier incentive for emerging companies, changes in IRS net operating loss change of ownership rules, a permanent or extended Research and Experimentation Credit, and a permanent or extended Orphan Drug credit.

Robert Beckman, president and CEO of Intergen Co. LP and chairman of BIO's Emerging Company section, presented the organization's tax agenda to a hearing of the House Ways and Means Committee last week...